Document is current

Article History

Accepted: 31 January 2024

First Online: 12 March 2024

Change Date: 20 April 2024

Change Type: Update

Change Details: The original version of this paper was updated to correct the family name of Matteo Alicandri Ciufelli.

Compliance with Ethical Standards

:

: EDC has received fees for consultation, speaker activity, and advisory boards from Sanofi, Regeneron, GlaxoSmithKline (GSK), Novartis and AstraZeneca. GO has received fees for consultation, speaker activity, and served on advisory boards for Sanofi, GSK, and Novartis. CP has received fees for consultation, speaker activity, advisory boards from Sanofi, Regeneron, GSK, Novartis, Chiesi, Firma. EC has received lecture fees from and participated in experts’ board meetings of GSK, Novartis, Sanofi, NOOS, and AstraZeneca. MC has received speaker and consultancy fees from Astra Zeneca, GSK, and Sanofi. CC has received lecture fees and participated in experts’ board meetings of GSK, Novartis, and Sanofi. G Senna has received speaker fees from Sanofi, AstraZeneca, and GSK. ST fees for lectures and advisory boards for GSK and SANOFI. VS has received lecture fees and participated in experts’ board meetings of GSK, Novartis, Sanofi, and AstraZeneca. MG has received lecture fees and participated in experts’ board meetings of GSK and Sanofi. MT has received consulting fees from Sanofi, GSK, and Novartis. FP has received consulting fees from Sanofi, Novartis, Chiesi, Menarini, Firma, and Deca. FRC has received lecture fees and participated in experts board meetings of GSK, Novartis, and Sanofi. ILM has received lecture fees and participated in experts’ board meetings of Sanofi. The other authors declare no conflict of interest. LC has received fees for consultation, speaker activity, and advisory boards from Sanofi, GlaxoSmithKline (GSK), Novartis, Menarini, Thermofisher, ALK and AstraZeneca. EN has received speaker and consultancy fees from Abbvie, Leo-Pharma, Novartis, Astra Zeneca, GSK, and Sanofi. MAC has received fees for consultation, speaker activity, advisory boards from Sanofi. GB has received lecture fees and participated in experts’ board meetings of Sanofi, GSK, Novartis, Abiogen, Aurora Biopharma. CC has received fees for consultation, speaker activity, and advisory boards from Sanofi, GlaxoSmithKline (GSK), menarini, Chiesi and AstraZeneca. MG has received advisory board fees or speaker fees from GlaxoSmithKline, Novartis, Sanofi-Genzyme, Valeas, DMG Italia, FIRMA, Aurora Biofarma, and Fenix Pharma. EH has received speaker activity and advisory board participation fees from Novartis, GlaxoSmithKline, Sanofi, Regeneron, AstraZeneca, Stallergenes-Greer, Circassia, and Nestlè Purina. AM has received speaker’s fees from Amicus Therapeutics, AstraZeneca, GSK, Novartis, Sanofi and Takeda and honoraria for attending advisory board meetings with, AstraZeneca, GSK, Novartis, Sanofi and Chiesi. AV has received speaker’s fees from AstraZeneca, GSK, Novartis, Sanofi and Chiesi and honoraria for attending advisory board meetings with, AstraZeneca, GSK, Novartis, Sanofi. PFM has received lecture fees and participated in experts board meetings of GSK and Sanofi. EP, SG, DM, has none conflict of interest. GS has received speaker fee and research grant by AstraZeneca, GSK, Novartis, Sanofi.